###### Strengths and limitations of this study

-   This is a systematic review of all quantitative and qualitative studies on physicians' treatment decisions and estimation of risk in acute coronary syndrome patients.

-   This will offer comprehensive and high level of evidence of the impact of patients' health-related quality of life on treatment decisions.

-   The measurement of quality of life may be based on dissimilar tools and may have its own limitations on estimating outcomes.

-   Studies that will be included in the review will only be limited to English, and this could lead to information bias.

Introduction {#s1}
============

Acute coronary syndrome (ACS) is one of the most common set of conditions that patients in emergency departments present with and which often leads to hospitalisation.[@R1] It is characterised by a number of clinical symptoms including unstable angina, non-ST-segment elevation myocardial infarction (MI) and ST-segment elevation MI.[@R1] The definitions of ACS depend on multiple range of activities including history taking, physical examination and reviews of electrocardiography, chest radiograph and cardiac biomarker test results.[@R1] Evidence from the literature shows that risk stratification is an essential prerequisite to decision-making, particularly when determining whether (1) patients will be treated in a coronary care unit or monitored step-down unit, (2) treatment will be invasive or non-invasive or (3) prognosis will be good or bad.[@R2] For the interest of this review, we will use either of the ACS diagnosis described by the authors in the primary study in order to include as many studies as possible.

Physicians have developed a number of multivariable risk assessment methods to help them provide a comprehensive assessment of risk and an accurate method of prognosis for patients with ACS.[@R5] These methods thereafter inform the treatment choice based on strategies that include percutaneous coronary intervention (PCI) and coronary angiography.[@R6] Despite the existence of these risk assessment techniques, however, physicians still use their clinical intuition to prescribe therapies and estimate potential benefit and harm.[@R8] Whether, and the extent to which, patients' health-related quality of life (HRQoL) influences this treatment choice is unclear in the literature. To date, HRQoL has several measurements with different scales, number of items, scoring calculation and interpretation. For example, Short Form 6, 12 and 36 dimension (SF-6D, SF-12 and SF-36),[@R10] Seattle Angina Questionnaire (SAQ),[@R13] Duke Activity Status Index (DASI),[@R15] Nottingham Health Profile (NHP)[@R16] and the Euro-Qol 5 dimensions three-level or five-level measures were some of the validated tools used to measure HRQoL. In this review, no a priori definition is specified in order to be more inclusive of a broad range of literature.

Few studies report on what factors influence physicians' decision-making in terms of treatment and risk assessment for ACS patients. For example, some studies report that being in high-risk clinical subgroups such as old age, male gender as well as having diabetes, renal failure, other cardiac comorbidities or a previous history of ACS are significant factors that influence this decision-making.[@R8] Unfortunately, these group of patients are also at high risk of increased adverse outcomes of ACS management.[@R20] However, evidence of the impact of HRQoL on decision-making and risk assessment is lacking. 'Impact\' in this review is referred to a situation where treatment risk estimation was modified or altered as a result of HRQoL.

A review in the USA[@R21] found that that several patients with ACS consider HRQoL while deciding to choose a treatment strategy although the survival benefit is similar among the available therapies. In particular, the review noticed that there were variations in preferences over the duration of HRQoL. Some patients chose easy treatment strategy that brings favourable HRQoL for short duration---for instance, patients chose PCI instead of CABG. To the contrary, other patients chose a complex treatment strategy to have a favourable QoL for longer period of time---for instance, patients chose CABG instead of PCI. Most patients understood less these existing trade-offs. It is against this impact that the review recommended that physicians should have to consider advising their patients about the HRQoL benefit before deciding to choose a treatment strategy. Thus, there will be a need to consider provide objective information on HRQoL by physicians. Furthermore, the literature review revealed that clinical trials, treatment guidelines and polices should have to consider HRQoL while deciding to prescribe among treatment strategies.

Several definitions have been used to measure bleeding in hospital and post-discharge periods, including Bleeding Academic Research Consortium (BARC). Although evidence on the relationship between bleeding event and QoL is scarce, the existing evidence demonstrated worse QoL following a bleeding event.[@R22] For example, Amin *et al* found a 24% prevalence of bleeding among patients with ACS undergoing PCI, and the 6 month QoL was worse.[@R22] Furthermore, evidence show the association between change in QoL and mortality.[@R24] Nevertheless, the degree to which this HRQoL affects the estimation of the risk of mortality or bleeding events in patients with ACS is uncertain.[@R8]

Therefore, this study will review the available evidence on HRQoL and other factors affecting physicians' therapy decisions and their assessment of risk for ACS patients. In particular we will review, (1) the status of HRQoL in patients with ACS before and after treatment, (2) the impact of HRQoL on physician's treatment decision in ACS patients and (3) the impact of patient's HRQoL on physician's estimation of the potential outcomes such as mortality and bleeding risk.

Methods and design {#s2}
==================

Population {#s2a}
----------

The systematic review will include studies on physicians who screen and diagnose patients with ACS and prescribe PCI or angiography therapy.

Study design {#s2b}
------------

The systematic review will consider quantitative and qualitative studies of good quality published before June 2018.

Search strategy {#s2c}
---------------

We will perform the following steps to undertake the searching strategy. First, we will carry out a limited search through Google scholar and MEDLINE in order to develop key terms for the three pre-defined concepts relating to the research question.: concept 1 (predictors, factors, quality of life or life quality), concept 2 (physician therap\*, percutaneous coronary intervention, percutaneous transluminal angioplasty, PTA, PTCA, PCI, angiography, revascularisation, bleeding events, mortality, death, clinical intuition, perceived benefit, perceived risk, risk stratification, estimated benefit or estimated risk) and concept 3 (ACS, coronary heart disease, MI or heart infarction). Second, we will carry out a full search (online [supplementary annex 1](#SP1){ref-type="supplementary-material"}) using all identified keywords and index terms across the following databases: MEDLINE, PubMed, CINAHL, SCOPUS and Web of Sciences. Concepts 1, 2 and 3 will be connected by 'AND' to run the full searching strategy in the aforementioned databases. Next, titles and abstracts from each database will be screened and relevant titles/abstracts selected for a full text appraisal. Finally, we will undertake backward and forward citation chaining of relevant documents. The search will also include unpublished studies or grey literature from ProQuest Dissertations and Theses (PQDT), WHO, Health department Data and other health data repositories.
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[Figure 1](#F1){ref-type="fig"} describes the schematic presentation of the search strategy using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

![A schematic presentation of the systemic search and use of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for Protocol for reporting the findings.](bmjopen-2018-026595f01){#F1}

Study selection {#s2d}
---------------

Prior to inclusion in the review, two primary but independent reviewers, HAG and BK, will assess the selected papers for methodological validity using a standardised Joanna Briggs Institute (JBI) appraisal instruments[@R28] (online [supplementary annex 2](#SP1){ref-type="supplementary-material"}). Any disagreement will be resolved by consensus among the research team.

Quality assessment {#s2e}
------------------

The two primary reviewers will independently assess the methodological quality of the included studies using an appraisal form developed by the JBI (online [supplementary annex 2](#SP1){ref-type="supplementary-material"}). In addition, we will assess the risk of bias via the Agency for Healthcare Research and Quality (AHRQ) criteria.[@R29]

Data extraction {#s2f}
---------------

Quantitative and qualitative data will be extracted from papers based on the JBI data extraction tool (online [supplementary annex 3](#SP1){ref-type="supplementary-material"}). We will extract relevant information from all articles included in the review into a spreadsheet. Whenever, there is missing or unclear data, we will contact authors of primary studies. Both primary reviewers will independently check the data extraction.

Outcomes {#s2g}
--------

The review will consider the following physician outcomes:Prescription of PCI for patients with ACS.Prescription of angiography for ACS patients.Estimation of mortality risk to ACS patients.Estimation of bleeding events for ACS patients.

Definitions and measurements of estimated (perceived) mortality and bleeding events benefit are described elsewhere.[@R8] Briefly, bleeding events were measured using Thrombolysis in Myocardial Infarction (TIMI), Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) and the ACUITY bleeding criteria

Exposures {#s2h}
---------

The primary exposure in this review will be HRQoL as defined by a number of HRQoL instruments. These will include the Short Form 6, 12 and 36 dimensions (SF-6D, SF-12 and SF-36, respectively),[@R10] SAQ,[@R13] DASI,[@R15] NHP[@R16] and the Euro-Qol 5 dimensions three- or five-level measures (EQ-5D-3L or EQ-5D-5L). The secondary exposures or confounders will include age, sex, diabetes mellitus, renal failure, smoking, family history of cardiac illnesses, presenting with cardiac shock or cardiac arrest, other cardiac comorbidities and previous history of ACS.

Analysis {#s3}
========

A narrative synthesis of outcomes along with the exposure variable of selected studies will be demonstrated in the final review. We will include the following information to summarise the main data from the included studies: author (year), setting, study design, population, sample size, outcome and main findings. The factors for both outcomes, physicians' treatment decision and assessment of perceived risk, will be summarised into themes, and summary findings of each study included in the review will be presented in tables.

If data will be available, meta-regression and meta-analyses will be conducted to see the association of the factors with the aforementioned outcomes. We will assess the clinical and statistical heterogeneity before conducting the meta-analyses. The research team will check the clinical heterogeneity to decide which variable and outcome will be added in the meta-analysis. We will use standard Chi-square and I^2^ tests to diagnose the statistical heterogeneity, with significant heterogeneity detected at the p\<0.05. In addition, meta-analyses will be carried out separately for each outcome and each exposure of interest using RevMan-5 Software.[@R30] We will consider meta-analysis if I^2^ will be below 85%.[@R31] In order to calculate effect sizes, we will use a Mantel Haenszel statistical method with forest plots used to graphically depict the relationship between exposures of interest and outcomes or events.

Based on the degree of statistical heterogeneity, we will calculate a pooled unadjusted OR[@R32] estimates and their 95% CIs using random or fixed effect meta-analysis.[@R31] If the outcome is reported using continuous data, we will use a mean difference (MD) or standardised mean difference (SMD). MD will be used if all included studies use the same scale whereas SMD will be used if the included studies applied variety scales. If the number of studies that reported the exposure and outcome of interest will be small (n\<5), we will only consider fixed effect model irrespective of the level of heterogeneity.[@R33] We will consider pooling if at least two studies assess the outcomes and the exposures of interest. To assess the publication bias, we will use a funnel plot. We will also consider a sensitivity test via omitting and entering small studies and deviant results from the rest of the studies (outliers). The strength of the body of evidence will be assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE).

Ethics and dissemination {#s3a}
------------------------

This study will not require a formal ethical approval because it will not involve collection of primary data. To disseminate findings of the Review, we will use the following media: publishing in peer-reviewed journals, presenting on workshops, conference and sharing through a media release.

Patient and public involvement {#s3b}
------------------------------

No patient or public is involved as this is a review of studies.

Conclusion {#s4}
==========

This systematic review will provide evidence in support of, or against, the hypothesis that patients' HRQoL has a role in physicians' treatment decisions and in estimating the mortality and bleeding event risk for ACS patients. Particularly, this review will assess the impact that HRQoL, measured using validated instruments, has on prescribing PCI and angiography. Furthermore, the role of HRQoL on estimating mortality and bleeding events benefit will also enumerated. We will apply descriptive and inferential statistical analysis to summarise the quantitative data from the review and synthesise the qualitative component of the findings into themes. In general, the review will contribute to the clinical evidence base on what drives clinical intuition during the treatment decision-making for ACS patients.
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